Eisai Co. Ltd. said its breast cancer drug Halaven remains available despite its rejection by the U.K.'s National Institute for Health and Care Excellence for use in a different setting.
Halaven, or eribulin, is still available to treat adults with locally advanced or metastatic breast cancer who have received at least two chemotherapeutic regimens. NICE had rejected the drug for use in patients who had received one chemotherapy regimen, saying the treatment is not cost effective.
Eisai said it is "extremely disappointed" with the regulator's decision but will continue further dialogue with NICE.
